News

Nine Startups and Ten Researchers Share Their Innovations at Oregon Bioscience Showcase 2017

FOR IMMEDIATE RELEASE – Oct. 24, 2017 NINE STARTUPS AND TEN RESEARCHERS SHARE THEIR INNOVATIONS AT OREGON BIOSCIENCE SHOWCASE 2017 Oregon Governor Kate Brown  (@OregonGovBrown) will provide opening comments to highlight the entrepreneurs’ event #OregonBio2017  CONTACT: Denise McCarty, Executive Director, (503) 548-4432 Dianne Danowski Smith, Board member, (503) 201-7019, @OregonBio (Portland, Ore.) -- Nine emerging device, diagnostic and digital health startups will get just 10 minutes to highlight their companies at Oregon Bioscience Showcase 2017’s 6th Annual Company Pitch Showcase on Monday, Oct. 30 at 1 p.m. in OMSI’s Empirical Theater. To kick off the event, Governor Kate Brown will welcome the next generation of researchers and startups. Hundreds of attendees will get the direct line on formative concepts from these startups such as how artificial intelligence is being used to extract biological information; how wearable technologies will precisely track patients’ responses to interventions; how to help developing countries diagnose and manage parasites that cause such diseases as malaria; and how a USB-drive-sized device with a humanized microscopic animal represents an individual patient’s version of a disease, among other technologies. Oregon Bio worked closely with the State of Oregon’s bioscience Signature Research Center, OTRADI (Oregon Translational Research and Development Institute) to [...]

Nine Startups and Ten Researchers Share Their Innovations at Oregon Bioscience Showcase 2017 2017-10-24T16:12:06+00:00

Governor Kate Brown to Launch Bio Researchers’ and Entrepreneurs’ Sessions at the Oregon Bioscience Showcase

FOR IMMEDIATE RELEASE – Oct. 17, 2017 GOVERNOR KATE BROWN TO LAUNCH BIO RESEARCHERS’ AND ENTREPRENEURS’ SESSIONS AT THE OREGON BIOSCIENCE SHOWCASE The first-ever appearance by an Oregon Governor at the entrepreneurs’ event will highlight the researchers’ fast pitch and the company showcase #OregonBio2017 CONTACT: Denise McCarty, Executive Director, (503) 548-4432 Dianne Danowski Smith, Board member, (503) 201-7019, @OregonBio (Portland, Ore.)  - Attendees at the Oregon Bioscience Showcase will hear from Governor Kate Brown (@OregonGovBrown) as she launches the high-profile event with opening remarks and welcomes the next generation of researchers and start-up companies. The Oregon Bioscience Showcase 2017 will take place on Oct. 30 at 1 p.m. in OMSI’s Empirical Theater. With just three minutes each, ten high school and academic researchers will compete, presenting their projects to the 200+ bioscience professionals in the audience. This is their unique opportunity to discuss their emerging research and its impact in the local and global bioscience ecosystem. Here’s who they are and their focus: Cynthia Bui, 12th Grade, Madison High School, Portland A Genetic Approach to Designing a Novel Biological Sensor to Monitor Water Contamination Monica Chang, 11th Grade, Camas High School, Camas, Washington A Closer Look at Memory: The Effect [...]

Governor Kate Brown to Launch Bio Researchers’ and Entrepreneurs’ Sessions at the Oregon Bioscience Showcase 2017-10-17T10:00:02+00:00

Portland-Based Immuno-oncologist Dr. Bernard A. Fox To Present at Siena, Italy Conference

October 7, 2017 FOR IMMEDIATE RELEASE Contact: Patricia Pearson, ppearson@ubivac.com Siena, Italy—Dr. Bernard A. Fox, internationally known expert in immuno-oncology will meet with other cancer experts here Saturday to discuss recent advances in treatmentsthat hold promise for improved treatments and increased survival for patients with cancer. Dr. Fox, chief executive officer, UbiVac, www.ubivac.com, will discuss the latest research in agonistic antibodies in an era of antagonistic antibodies. He will provide insights into mono-therapy, as well as combination and/or sequential therapies from his latest publication on the topic and UbiVac’s evaluation of patients enrolled on their phase II clinical trial for NSCLC. The event, “A Vision of Immuno-Oncology: The Siena Consensus,” will be held October 7, 3 to 6 pm, as a “think tank” of those involved in developing the latest cancer immunotherapies. It is sponsored by the Network Italiano per la Bioterapia del Tumori/The Italian Network for Cancer Biotherapy (NIBIT), is part of its XVth Cancer Bio-Immunotherapy Meeting. A non-profit foundation, NIBIT was formed in 2004 and is focused on bringing together groups involved in clinical and pre-clinical research in cancer immunotherapy and biotherapy to discuss the latest advances in the field. This meeting seeks to help build consensus among [...]

Portland-Based Immuno-oncologist Dr. Bernard A. Fox To Present at Siena, Italy Conference 2017-10-13T10:22:37+00:00

Oregon’s Life Science Industry on Display: Oregon Bioscience Showcase 2017

The first-ever Oregon Bioscience Showcase, on October 30, combines the Research Fast Pitch and Company Pitch Showcase, presenting emerging companies and rising-star researchers #OregonBio2017 CONTACT: Denise McCarty, Executive Director, (503) 548-4432 Dianne Danowski Smith, Board member, (503) 201-7019, @OregonBio (Portland, Ore.)  - Three minutes. That’s all the time nine local researchers and students will have to showcase their research and projects to a room full of bioscience professionals, enthusiasts and judges. This is their unique opportunity to discuss their emerging research and its impact in the local and global bioscience ecosystem. But before the selected researchers take center stage, nine emerging companies in various funding cycles in the device, diagnostics, and digital health sectors will get a mere 10 minutes to unveil their secret sauce to the audience as part of the 6th annual Company Pitch Showcase. Judges and the audience will have an opportunity to ask questions after their pitch as well as meet the entrepreneurs between pitch sessions. Company executives, entrepreneurs; investors; business, economic development and life science professionals; researchers; vendors; and STEM students are all invited to the Oregon Bioscience Showcase 2017 on Oct. 30, from 1 to 6 p.m. at OMSI’s Empirical Theater. The Showcase event [...]

Oregon’s Life Science Industry on Display: Oregon Bioscience Showcase 2017 2017-09-22T09:25:36+00:00

Why UO’s Knight Campus will boost Oregon’s fortunes (guest column)

The $1B project still needs lawmakers to approve $100M in bonds, an investment its new director says will bring together the whole state. Patrick Phillips The University of Oregon will break ground on the $1 billion Phil and Penny Knight Campus for Accelerating Scientific Impact this fall —made possible by a $500 million donation from the Knights — and the labs, classrooms, prototyping space and other core facilities will be the foundation for new scientific activities that will transform research at the university. As a biologist who has spent nearly 20 years at the university, I am excited and energized to have the facilities and resources needed to turn scientific discoveries into treatments, products and innovations that benefit all of society. But UO cannot do it alone. For the first phase of the project, we have asked state lawmakers to partner by providing $100 million in bonds for construction of one of the buildings. No tuition dollars or state funding are needed for the ongoing operations and activities supported by the buildings, so the state’s initial investment will be matched better than 10 to one. You only get one chance to lay the foundation for something with lasting impact, which [...]

Why UO’s Knight Campus will boost Oregon’s fortunes (guest column) 2017-06-23T09:35:24+00:00

Portland biotech startup foresees rapid growth from HIV test

Elizabeth Hayes, Staff Reporter, Portland Business Journal Typically, an HIV diagnostic test takes a few hours to run and requires a laboratory. A Portland biosciences company is developing a hand-held test that can produce accurate results from a drop of blood in just 20 minutes — and estimate how recently the infection occurred. Sedia Biosciences Corp.’s rapid HIV test could potentially speed up diagnosis of the disease, especially in developing countries, and play a big role in slowing the global AIDS epidemic. It could also prove a vital tool in helping clinicians identify candidates for new “functional cures” that reduce viral levels to the point therapies can be suspended, said Ron Mink, Sedia’s president and chief science officer. Read more at bizjournals.com

Portland biotech startup foresees rapid growth from HIV test 2017-06-21T13:01:59+00:00

Drug price transparency bill will not lower Rx costs

David Beier, San Francisco Chronicle Why is drug price transparency legislation like the wolf in “Little Red Riding Hood”? It was because the wolf was pretending to be something he was not. Equally, there is state legislation that is pretending to be about transparency in drug pricing when it is really about limiting the profitability of biotech firms. That kind of government control would deter investment in new and innovative biopharmaceutical treatments. Under a bill introduced by state Sen. Ed Hernandez, D-West Covina (Los Angeles County), drug companies would be required to disclose their prices and offer detailed data about their cost. According to its supporters, the purported transparency SB17 requires is supposed to expose that drug company spending on an individual drug cannot justify the price. This assumption fundamentally misunderstands the drug development and financing process. Read more at sfchronicle.com.

Drug price transparency bill will not lower Rx costs 2017-05-19T13:18:33+00:00

DesignMedix’s malaria drug to enter clinical trials with support from NIH

NEW RELEASE - FOR IMMEDIATE RELEASE CONTACT: Sandra Shotwell, CEO, shotwell@designmedix.com, 503-348-0855 Portland OR: DesignMedix Inc., a drug development company targeting drug resistant infectious diseases, has entered into an agreement with the National Institutes of Health (NIH) that will pave the way for first-in-human clinical trials of DesignMedix’s malaria drug DM1157. The agreement is with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and builds on the strong package of preclinical data DesignMedix has developed to prepare its malaria drug for clinical trials. Under the agreement, NIH will sponsor a Phase I clinical trial of DM1157. The trial will be conducted at Duke Clinical Research Institute, and is expected to commence in late 2017. “Diseases like malaria are a significant hurdle to the health, productivity and prosperity of millions of people around the world,” said DesignMedix CEO Sandra Shotwell, noting that malaria parasites have developed resistance to almost every malaria drug currently available. “Our malaria drug is designed to overcome drug resistance. We believe it will make a positive impact on global health, and appreciate the support provided by NIAID’s services to achieve this key milestone: the first-in-human studies of our novel malaria treatment.” DesignMedix [...]

DesignMedix’s malaria drug to enter clinical trials with support from NIH 2017-04-10T10:40:41+00:00

Grant-supported interns available for your company

Oregon Bio is excited to partner with OHSU and OSU to connect member companies with qualified interns. We will help match your needs to highly motivated and qualified undergraduate and graduate level interns from OSU and OHSU. Timing for Ph.D. students can be flexible, by mutual arrangement. For more information, please contact Lynn Ekstedt, lynn.ekstedt@oregonstate.edu […]

Grant-supported interns available for your company 2017-04-06T10:16:35+00:00

OTRADI Bioscience Incubator Creates Smart Health Annex for Digital Health Startups

The Rest of the Story: Oregon Bioscience Association’s 2016-’17 Annual Report Dylan Vance and his team at Jupiter Devices have a vision for a commercially successful product that could one day help millions of diabetics receive blood sugar readings in a noninvasive, accurate and efficient way. But transforming that product vision into commercial success also requires a bold vision of the kind of environment that can bring their idea to reality. Enter the OTRADI Bioscience Incubator’s new Smart Health Annex. “We were looking for more than just space,” said Vance, CEO of Jupiter, the first startup to take up residence at the incubator’s digital health themed annex. “We were looking for people who understand not just what it is we’re doing, but also how scientific research turns into medical products.” The Smart Health Annex is connected to OTRADI’s highly successful Bioscience Incubator (OBI), which now houses a total of 17 bioscience startups in its building at Southwest Macadam Avenue. The complex was initially set-up to offer young bio companies office space, wet-labs and other facilities often financially or logistically out of reach for bio startups. But as Vance and OTRADI Executive Director Jennifer Fox point out, the need for mentoring [...]

OTRADI Bioscience Incubator Creates Smart Health Annex for Digital Health Startups 2017-04-05T16:41:22+00:00